IL139672A - Glucocorticoid receptor antagonists for the tretment of dementia - Google Patents
Glucocorticoid receptor antagonists for the tretment of dementiaInfo
- Publication number
- IL139672A IL139672A IL13967298A IL13967298A IL139672A IL 139672 A IL139672 A IL 139672A IL 13967298 A IL13967298 A IL 13967298A IL 13967298 A IL13967298 A IL 13967298A IL 139672 A IL139672 A IL 139672A
- Authority
- IL
- Israel
- Prior art keywords
- dementia
- glucocorticoid receptor
- receptor antagonist
- tretment
- receptor antagonists
- Prior art date
Links
- 206010012289 Dementia Diseases 0.000 title abstract 2
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 title abstract 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- 229940044551 receptor antagonist Drugs 0.000 abstract 2
- 239000002464 receptor antagonist Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 abstract 1
- 229960003248 mifepristone Drugs 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8570398P | 1998-05-15 | 1998-05-15 | |
| PCT/US1998/020908 WO1999059596A1 (en) | 1998-05-15 | 1998-10-05 | Glucocorticoid receptor antagonists for the treatment of dementia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL139672A0 IL139672A0 (en) | 2002-02-10 |
| IL139672A true IL139672A (en) | 2005-11-20 |
Family
ID=22193399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13967298A IL139672A (en) | 1998-05-15 | 1998-10-05 | Glucocorticoid receptor antagonists for the tretment of dementia |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6369046B1 (https=) |
| EP (1) | EP1076562B1 (https=) |
| JP (3) | JP2003505336A (https=) |
| KR (1) | KR20010043630A (https=) |
| CN (1) | CN1130200C (https=) |
| AT (1) | ATE317699T1 (https=) |
| AU (1) | AU756818B2 (https=) |
| CA (1) | CA2328411C (https=) |
| DE (1) | DE69833502T2 (https=) |
| IL (1) | IL139672A (https=) |
| NZ (1) | NZ507449A (https=) |
| WO (1) | WO1999059596A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6620802B1 (en) * | 1999-11-23 | 2003-09-16 | Corcept Therapeutics, Inc. | Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist |
| WO2001039664A1 (en) * | 1999-12-02 | 2001-06-07 | The General Hospital Corporation | Method and apparatus for measuring indices of brain activity |
| US20010046470A1 (en) * | 2000-05-10 | 2001-11-29 | Kieko Morita | Diagnoses and treatment of disorders using an alternative glucose pathway |
| DE60238671D1 (de) * | 2001-05-04 | 2011-02-03 | Corcept Therapeutics Inc | Verwendung von glucocorticoid-rezeptor-spezifischen antagonisten zur behandlung von delirium |
| US7163934B2 (en) | 2001-05-04 | 2007-01-16 | Corcept Therapeutics, Inc. | Methods for treating delirium glucocorticoid receptor-specific antagonists |
| AU2002319665B2 (en) | 2001-07-23 | 2006-09-21 | Corcept Therapeutics, Inc. | Methods for preventing antipsychotic-induced weight gain |
| IL160649A0 (en) * | 2001-08-31 | 2004-07-25 | Corcept Therapeutics Inc | Methods for inhibiting cognitive deterioration in adults with down syndrome |
| US7326697B2 (en) * | 2002-04-29 | 2008-02-05 | Corcept Therapeutics, Inc. | Methods for increasing the therapeutic response to electroconvulsive therapy |
| CN1665515A (zh) * | 2002-07-02 | 2005-09-07 | 科塞普特治疗公司 | 治疗与干扰素α治疗相关的精神病的方法 |
| FR2850022B1 (fr) * | 2003-01-22 | 2006-09-08 | Centre Nat Rech Scient | Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications |
| US7473903B2 (en) * | 2003-02-12 | 2009-01-06 | General Electric Company | Method and apparatus for deposited hermetic cover for digital X-ray panel |
| ES2564187T3 (es) * | 2005-04-05 | 2016-03-18 | Yale University | Agentes de modulación de glutamato en el tratamiento de trastornos mentales |
| US7983740B2 (en) * | 2006-12-22 | 2011-07-19 | Washington University | High performance imaging system for diffuse optical tomography and associated method of use |
| US9480425B2 (en) * | 2008-04-17 | 2016-11-01 | Washington University | Task-less optical mapping of dynamic brain function using resting state functional connectivity |
| EP2504455A4 (en) * | 2009-11-24 | 2013-05-22 | Commw Scient Ind Res Org | METHODS, KITS AND REAGENTS FOR DIAGNOSIS, DIAGNOSTIC SUPPORT AND / OR MONITORING THE PROGRESS OF A NEUROLOGICAL SENSE |
| EP2576582B1 (en) * | 2010-05-26 | 2019-09-18 | Corcept Therapeutics, Inc. | Treatment of muscular dystrophy |
| US10500216B2 (en) | 2011-11-18 | 2019-12-10 | Corcept Therapeutics, Inc. | Optimizing mifepristone absorption |
| WO2015187988A1 (en) * | 2014-06-04 | 2015-12-10 | Intellimedix | Composition and methods of treating epilepsy and/or epilepsy-related disorders |
| US9943526B2 (en) | 2015-04-21 | 2018-04-17 | Corcept Therapeutics, Inc. | Optimizing mifepristone levels for cushing's patients |
| US10261310B2 (en) | 2016-06-27 | 2019-04-16 | Amazon Technologies, Inc. | Amorphous silicon layer as optical filter for thin film transistor channel |
| PH12022551430A1 (en) | 2019-12-11 | 2023-11-20 | Corcept Therapeutics Inc | Methods of treating antipsychotic-induced weight gain with miricorilant |
| US12194036B2 (en) * | 2022-07-07 | 2025-01-14 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA8231B (en) * | 1981-01-09 | 1982-11-24 | Roussel Uclaf | New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained |
| US5348729A (en) | 1988-11-30 | 1994-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | Evaluative means for detecting inflammatory reactivity |
| FR2696934B1 (fr) | 1992-10-20 | 1995-06-02 | Conservatoire Nal Arts Metiers | Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir. |
| IL110309A0 (en) * | 1993-07-15 | 1994-10-21 | Univ Kentucky Res Found | A method of protecting against neuron loss |
| IL118974A (en) | 1995-08-17 | 2001-09-13 | Akzo Nobel Nv | History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them |
| DE69737791D1 (de) | 1996-04-09 | 2007-07-19 | Univ Edinburgh | Verwendung von 7-alpha-substituierten steroiden zur behandlung von neuropsychiatrischen erkrankungen |
-
1998
- 1998-10-05 KR KR1020007012796A patent/KR20010043630A/ko not_active Withdrawn
- 1998-10-05 CN CN98814043A patent/CN1130200C/zh not_active Expired - Fee Related
- 1998-10-05 JP JP2000549261A patent/JP2003505336A/ja active Pending
- 1998-10-05 AT AT98950912T patent/ATE317699T1/de not_active IP Right Cessation
- 1998-10-05 DE DE69833502T patent/DE69833502T2/de not_active Expired - Lifetime
- 1998-10-05 CA CA002328411A patent/CA2328411C/en not_active Expired - Fee Related
- 1998-10-05 IL IL13967298A patent/IL139672A/xx not_active IP Right Cessation
- 1998-10-05 WO PCT/US1998/020908 patent/WO1999059596A1/en not_active Ceased
- 1998-10-05 NZ NZ507449A patent/NZ507449A/en not_active IP Right Cessation
- 1998-10-05 AU AU96833/98A patent/AU756818B2/en not_active Ceased
- 1998-10-05 EP EP98950912A patent/EP1076562B1/en not_active Expired - Lifetime
-
1999
- 1999-02-04 US US09/246,780 patent/US6369046B1/en not_active Expired - Lifetime
-
2008
- 2008-11-18 JP JP2008294967A patent/JP2009051864A/ja active Pending
-
2009
- 2009-05-22 JP JP2009124741A patent/JP2009185067A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL139672A0 (en) | 2002-02-10 |
| CA2328411C (en) | 2008-12-16 |
| CN1292701A (zh) | 2001-04-25 |
| EP1076562B1 (en) | 2006-02-15 |
| KR20010043630A (ko) | 2001-05-25 |
| ATE317699T1 (de) | 2006-03-15 |
| WO1999059596A1 (en) | 1999-11-25 |
| DE69833502D1 (de) | 2006-04-20 |
| JP2009051864A (ja) | 2009-03-12 |
| DE69833502T2 (de) | 2006-09-28 |
| AU9683398A (en) | 1999-12-06 |
| NZ507449A (en) | 2003-08-29 |
| JP2003505336A (ja) | 2003-02-12 |
| US6369046B1 (en) | 2002-04-09 |
| HK1032535A1 (en) | 2001-07-27 |
| AU756818B2 (en) | 2003-01-23 |
| CA2328411A1 (en) | 1999-11-25 |
| CN1130200C (zh) | 2003-12-10 |
| JP2009185067A (ja) | 2009-08-20 |
| EP1076562A1 (en) | 2001-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL139672A (en) | Glucocorticoid receptor antagonists for the tretment of dementia | |
| CY1108562T1 (el) | Μεθοδοι για την προληψη προσληψης βαρους η οποια προκαλειται απο αντιψυχωτικες θεραπειες | |
| WO2002076390A3 (en) | Methods for treating stress disorders using glucocorticoid receptor-specific antagonists | |
| CA2302586A1 (en) | Methods for treating psychosis associated with glucocorticoid related dysfunction | |
| HK1047050A1 (zh) | 治疗轻度智力机能缺陷的方法 | |
| NO20003534L (no) | Progesteronreseptor-modulatorforbindelser, farmasøytiske sammensetninger inneholdende disse og anvendelsen av forbindelsene | |
| MX9704640A (es) | Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion. | |
| TR199801679T2 (xx) | Osteoporoz i�in birle�tirme terapisi. | |
| IL160649A0 (en) | Methods for inhibiting cognitive deterioration in adults with down syndrome | |
| IL164793A0 (en) | Methods for increasing the therapeutic response toelectroconvulsive therapy ("ect") | |
| WO2004069202A3 (en) | Antiglucocorticoids for the treatment of postpartum psychosis | |
| DK1467762T3 (da) | Anvendelse af en H1-antagonist og rimexolon som et sikkert steroid til behandling af rhinitis | |
| IL158744A0 (en) | Methods for treating delirium using glucocorticoid receptor-specific antagonists | |
| EP1726307A3 (en) | Methods for treating psychosis associated with glucocorticoid related dysfunction | |
| DK1165184T3 (da) | Estrogenreceptor-beta antagonisme og knoglesygdomme | |
| WO2002020526A3 (en) | Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents | |
| MX9706967A (es) | Indazolcarboxamidas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| MM9K | Patent not in force due to non-payment of renewal fees |